North Central Cancer Treatment Group (NCCTG) N0537: Phase II Trial of VEGF-Trap in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and/or a Taxane

Micro-Abstract Angiogenesis is an established target in metastatic breast cancer (MBC). Aflibercept (vascular endothelial growth factor [VEGF]-trap) is a humanized fusion protein which binds VEGF-A, VEGF-B, and placental growth factors PIGF-1, and PIGF-2. A phase II study was conducted to test the s...

Full description

Bibliographic Details

Published in:	Clinical breast cancer 2012-12, Vol.12 (6), p.387-391
Main Authors:	Sideras, Kostandinos, Dueck, Amylou C, Hobday, Timothy J, Rowland, Kendrith M, Allred, Jacob B, Northfelt, Donald W, Lingle, Wilma L, Behrens, Robert J, Fitch, Tom R, Nikcevich, Daniel A, Perez, Edith A
Format:	Article
Language:	eng
Subjects:	Adenocarcinoma - drug therapy Adenocarcinoma - mortality Adenocarcinoma - pathology Adult Aged Angiogenesis Anthracyclines - administration & dosage Antineoplastic Agents - adverse effects Antineoplastic Agents - therapeutic use Antineoplastic Combined Chemotherapy Protocols - therapeutic use Breast cancer Breast Neoplasms - drug therapy Breast Neoplasms - mortality Breast Neoplasms - pathology Bridged-Ring Compounds - administration & dosage Chemotherapy, Adjuvant Cooperative group Drug Resistance, Neoplasm - drug effects Female Hematology, Oncology and Palliative Medicine Humans Medical Oncology - organization & administration Middle Aged Monoclonal antibody Neoplasm Metastasis Obstetrics and Gynecology Receptors, Vascular Endothelial Growth Factor - adverse effects Receptors, Vascular Endothelial Growth Factor - therapeutic use Recombinant Fusion Proteins - adverse effects Recombinant Fusion Proteins - therapeutic use Societies, Medical Survival Analysis Taxoids - administration & dosage United States
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!